id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0461-0007,FDA,FDA-2003-E-0461,"Certificate Extending Patent Term from U.S. Patent and Trademark Office to Millennium Pharmaceuticals, Inc.",Rule,Certificate Extending Patent Term,2007-03-15T04:00:00Z,2007,3,,,2025-10-30T23:52:50Z,,0,0,09000064804a290d
FDA-2003-E-0461-0006,FDA,FDA-2003-E-0461,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-10-21T04:00:00Z,2004,10,,,2025-10-30T23:51:32Z,,0,0,09000064804a290c
FDA-2003-E-0461-0005,FDA,FDA-2003-E-0461,Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,General Notice,2004-03-23T05:00:00Z,2004,3,2004-03-19T05:00:00Z,,2025-10-30T23:49:23Z,04-6159,0,0,09000064804a290b
FDA-2003-E-0461-0004,FDA,FDA-2003-E-0461,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-03-05T05:00:00Z,2004,3,,,2025-10-30T23:44:21Z,,0,0,09000064804a290a
FDA-2003-E-0461-0003,FDA,FDA-2003-E-0461,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-01-16T05:00:00Z,2004,1,,,2025-10-30T23:40:36Z,,0,0,09000064804a2909
FDA-2003-E-0461-0002,FDA,FDA-2003-E-0461,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-24T05:00:00Z,2003,11,,,2025-10-30T23:38:39Z,,0,0,09000064804a2907
FDA-2003-E-0461-0001,FDA,FDA-2003-E-0461,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-09-29T04:00:00Z,2003,9,,,2025-10-30T23:26:44Z,,0,0,09000064804a28fb